About Us

At LatusPet, we apply groundbreaking science to our love of pets and our concerns for their health

Our Story

A compelling tale follows Bobo, a former venture capitalist, his loyal dogs, and an entrepreneurial pursuit that transformed lives. Bobo was inspired by discussions about pet health startups and remembered the helplessness he felt as a boy when his Central Asian shepherd dogs fell ill and no treatment could save them because the disease progressed beyond the point of return. Determined to improve pet healthcare, Bobo consulted with his former Oxford Professor, Daniel Anthony, an expert in multi-omics approaches to human health. The idea of adapting this technology for pets resonated with Daniel. Motivated by this shared vision, Bobo developed LatusPet's groundbreaking testing technology, SINO, promising pet owners extended, quality time with their cherished animals.

Meet Team LatusPet!

Dr. Bobojon Nazarov

CEO

Bobojon is an entrepreneur with over a decade of experience in finance, investment, and the creation of ventures. He founded Latus Therapeutics, where he conceptualised, launched, and successfully delivered two clinical trials. Bobojon's professional journey includes being a biotech investor; he worked for Merck Ventures, Life Sciences Partners and as a fund manager led Daten Capital (L/S biotech fund). Before these roles, Bobojon worked in the financial sector as a Financial Analyst at the Chicago Mercantile Exchange and IHS Markit.

Prof. Daniel Anthony

CSO

Daniel's research at the University of Oxford focuses on identifying how inflammation contributes to the outcome of acute and chronic brain injury or infection and identifying novel biomarkers to diagnose disease and predict progression. Daniel is also a serial biotech entrepreneur; he launched several biotech start-ups, including diagnostic companies based on multi-omics aproaches.

Prof. Graham Richards

CBE, FRS, FRSC, Chem

Sr. Scientific Advisor

Graham was the first head of the Chemistry Department at the University of Oxford. His research focused on in-silico drug discovery, and he pioneered computer-aided molecular drug discovery. He also co-founded two biotech funds: OSE, raising £600m at inception & IP Group with NAV of > £1.5b.

Prof. Paul Finn

Sr. Scientific Advisor

Paul is the CSO of Oxford Drug Design, where his research focuses on in-silico drug discovery. He was also Head of Computational Chemistry at GSK, Pfizer and TopoTarget. Paul is also co-inventor of Belinostat, a therapy for T-Cell Lymphomas.

Prof. Grant Churchill

Sr. Scientific Advisor

Grant’s research at the University of Oxford focuses on understanding how small molecules inside cells act as messengers to control physiology and how mimics of these messenger molecules can be used as chemical tools. Grant is also a biotech entrepreneur who successfully delivered a therapy from bench to market.